Pathogenetically based therapy for cyclic mastalgia

Tazina T.V.

Academician I.P. Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation, Ryazan, Russian Federation
Objective. To present their own experience with Indinol Forto in the treatment of breast pain in cyclic mastalgia in patients with benign mammary dysplasia.
Materials and methods. Thirty-two women with confirmed benign mammary dysplasia who had taken Indinol Forto 200 mg twice daily before meal for 6 months were examined and treated in during the period 2017–2018. The patients’ mean age was 40.9±11.2 years.
Results. Reduced breast pain in cyclic mastalgia of varying intensity was noted in all the patients. Decreases in the sizes and number of cysts were confirmed by ultrasound. The drug was recorded to have good tolerance; no moderate or severe adverse events were noted.
Conclusion. The authors’ experience has confirmed that Indinol Forto can be used as one of the first-line agents in the treatment of cyclic mastalgia, including in patients with benign mammary dysplasia.


benign mammary dysplasia
cyclic mastalgia
indole carbinol
Indinol Forto


  1. Андреева Е.Н., Рожкова Н.И., Соколова Д.А. Доброкачественные дисплазии молочных желез: патогенетический вектор лечения. Обзор исследований, клинические рекомендации: информационный бюллетень. М.: Редакция журнала StatusPraesens; 2016. 24c. [Andreeva E.N., Rozhkova N.I., Sokolova D.A. Benign breast dysplasia: pathogenetic vector of treatment. A review of research, clinical practice guidelines: newsletter. Moscow: Editorial office of the journal StatusPraesens. 2016. 24 p. (in Russian)].
  2. Коган И.Ю., Мясникова М.О. Диагностика и лечение мастопатии. СПб.: Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова 2010. 32с. [Kogan I.J., Myasnikova М.О. Diagnosis and treatment of mastopathy. I.P. Pavlov Saint Petersburg State Medical University. 2010. 32 p. (in Russian)].
  3. Onstad M., Stuckey A. Benign breast disorders. Obstet. Gynecol. Clin. North Am. 2013; 40(3): 459-73.
  4. Письмо Министерства здравоохранения РФ от 7 ноября 2018 г. № 15-4/10/2-7235 «О направлении клинических рекомендаций (протокола лечения) "Доброкачественная дисплазия молочной железы"». [Letter of the Ministry of health of the Russian Federation dated November 7, 2018 N 15-4/10/2-7235 about the direction of clinical recommendations (treatment Protocol)"Benign dysplasia of breast cancer". (in Russian)].
  5. Iddon J., Dixon M. Mastalgia. BMJ. 2013; 347: f3288.
  6. Olawaiye A., Withiam-Leitch M., Danakas G., Kahn K. Mastalgia: a review of management. J. Reprod. Med. 2005; 50(12): 933-9.
  7. Радзинский В.Е., ред. Молочные железы и гинекологические болезни, М.; 2010. 304с. [Breast and gynecological diseases, ed. by V.E. Radzinskiy. Moscow, 2010. 304 p. (in Russian)].
  8. Silvera S., Rohan T. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Res. Treat. 2008; 110(3): 397-409.
  9. Коган И.Ю. Мастопатия: фиброзно-кистозная болезнь. Учебно-методическое пособие. СПб.: Изд-во Н-Л; 2008. 40с. [Kogan I.Yu. Mastopathy: fibrocystic disease. Educational and methodical manual. Saint-Petersburg.: Publishing house N-L; 2008. 40 p. (in Russian)].
  10. Plu-Bureau G., Lê M.G., Sitruk-Ware R., Thalabard J.C. Cyclical mastalgia and breast cancer risk: results of a French cohort study. Cancer Epidemiol. Biomarkers Prev. 2006; 15(6): 1229-31.
  11. Telang N.T., Suto A., Wong G.Y., Osborne M.P., Bradlow H.L. Induction by estrogen metabolite 16 alpha-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J. Natl. Cancer Inst. 1992; 84(8): 634-8.
  12. Трошина Е.А., Румянцев П.О., Алташина М.В., Плохая А.А. Влияние избыточной массы тела и ожирения на факторы риска развития рака молочной железы у женщин в постменопаузе. Ожирение и метаболизм. 2012; 9(3): 3-10. [Troshina Е.А., Rumyanstev P.O., Altashina М.V., Plohaya А.А. The impact of overweight and obesity on risk factors for development of breast cancer in postmenopausal women. Obesity and metabolism. 2012; 9(3): 3-10. (in Russian)].
  13. Ковалева Ю.В. Гормоны жировой ткани и их роль в формировании гормонального статуса и патогенезе метаболических нарушений у женщин. Артериальная гипертензия. 2015; 21(4): 356-70. [Kovaleva Ju.V. Adipose tissue hormones and their role in the formation of hormonal status and pathogenesis of metabolic disorders in women. Arterial hypertension. 2015; 21(4):356–70. (in Russian)].
  14. Телетаева Г.М. Цитокины и противоопухолевый иммунитет. Практическая онкология. 2007; 8(4): 211-8. [Teletaeva G.М. Cytokines and antitumor immunity. Practical Oncology. 2007; 8(4): 211-8. (in Russian)].
  15. Берштейн Л.М. Гормональный канцерогенез. Санкт-Петербург: Наука; 2000. 199с. [Berstein L.M. Hormonal carcinogenesis. Saint-Petersburg: Science, 2000. 199p. (in Russian)].
  16. Ahmad A., Sakr W.A., Rahman K.M. Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy. Curr. Drug Targets. 2010; 11(6): 652-66.

Received 14.08.2020

Accepted 03.09.2020

About the Authors

Tatyana V. Tazina, candidate of medical sciences, assistant professor of the Department of Surgery, Obstetrics and Gynecology, Faculty of Additional Supplementary Professional Education, I.P. Pavlov Ryazan State Medical University of Ministry of Health of Russian Federation.
Tel.: +7(910)644-85-28. E-mail: ORCID: 0000-0003-1029-0390, Researcher ID: D-7640-2018, SPIN: 7059-9793.
9 Vysokovoltnaya str., Ryazan, 390026, Russian Federation.

For citation: Tazina T.V. Pathogenetically based therapy for cyclic mastalgia.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2020; 9: 187-190 (in Russian).

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.